Literature DB >> 33457229

Bioinformatic gene analysis for potential biomarkers and therapeutic targets of diabetic nephropathy associated renal cell carcinoma.

Yunze Dong1, Wei Zhai2, Yunfei Xu1.   

Abstract

BACKGROUND: Numerous epidemiological studies have confirmed that diabetes can promote the development of malignant tumors. However, the relationship between renal cell carcinoma (RCC) and diabetic nephropathy (DN) is still controversial. This study aimed to investigate the genes that are co-expressed in DN and RCC in order to gain a better understanding of the relationship between these diseases, and to identify potential biomarkers and targets for the treatment of DN-related RCC.
METHODS: We evaluated the differentially expressed genes (DEGs) that are co-expressed in DN and RCC using a wide range of target prediction and analysis methods. Twenty-four genes were identified by intersecting the differential genes of 3 DN datasets and 2 RCC datasets. We predicted the micro-ribonucleic acids (miRNAs) of these genes that may be controlled using the miRNA Data Integration Portal (mirDIP) database, and rated them according to each data forecast based on the Comparative Toxicogenomics Database (CTD) and the StarBase database.
RESULTS: Four genes were associated with DN and RCC patients: the predicted miRNAs hsa-miR-200b-3p and hsa-miR-429 of fibronectin 1 (FN1); the predicted miRNA hsa-miR-29c-3p of collagen type 1 alpha 2 (COL1A2); the predicted miRNA hsa-miR-29c-3p of collagen type 3 alpha 1 (COL3A1); and the predicted miRNA hsa-miR-29a-3p and hsa-miR-200c-3p of glucose-6-phosphatase catalytic subunit (G6PC). These genes may serve as potential biomarkers or specific targets in the treatment of DN-related RCC.
CONCLUSIONS: A significant correlation was identified between DN and RCC. The FN1, COL1A2, COL3A1, and G6PC genes could be novel biomarkers of DN-related RCC. 2020 Translational Andrology and Urology. All rights reserved.

Entities:  

Keywords:  Gene analysis; biomarkers; diabetic nephropathy (DN); renal cell carcinoma (RCC)

Year:  2020        PMID: 33457229      PMCID: PMC7807343          DOI: 10.21037/tau-19-911

Source DB:  PubMed          Journal:  Transl Androl Urol        ISSN: 2223-4683


Introduction

Approximately 25% of people with diabetes develop renal complications. Diabetic nephropathy (DN), one of the major chronic complications of diabetes, has become the primary cause of end-stage kidney disease in the world (1,2). Statistics predict that the number of diabetic patients globally will reach 3.66 billion by the middle of the 21st century, with more than 100 million of them suffering from DN (3). Renal cell carcinoma (RCC) is a malignant genitourinary tumor accounting for 2% of adult cancers (4). The incidence and mortality of RCC increase at a rate of 2–3% each decade (5). However, the correlation between DN and RCC remains unclear and controversial. According to existing epidemiological reports, diabetes can significantly increase the risk of malignant tumors, including pancreatic and liver cancers, as well as RCC (6-9). Habib et al. found that diabetic patients were more likely to develop RCC than healthy individuals, with 14% of diabetic patients suffering from RCC, which is 5 times higher than the rate among healthy people (10). The incidence of RCC and diabetes is increasing. The elevated incidence of RCC, especially DN-associated RCC, should be afforded greater attention. In this study, we predicted the differentially expressed genes (DEGs) in RCC and DN, and performed a bioinformatics analysis on these co-expressed differential genes. We present the following article in accordance with the MDAR reporting checklist (available at http://dx.doi.org/10.21037/tau-19-911).

Methods

Gene expression profile data

Our datasets were drawn from the Gene Expression Omnibus (GEO) repository (http://www.ncbi.nlm.nih.gov/geo/). The data platforms for GSE99339 are GPL19109 [HG-U133_Plus_2] Affymetrix Human Genome U133Plus 2.0 Array [CDF: Brainarray HGU133Plus2_Hs_ENTREZG_v18] and GPL19184 [HG-U133A] Affymetrix Human Genome U133A Array [Custom Brain] array v18 ENTREZG CDF]. The data platform for GSE96804 is GPL17586 [HTA-2_0] Affymetrix Human Transcriptome Array 2.0 [transcript (gene) version]. The data platform for GSE47183 is GPL1670AffymetrixHumanGenomeU133Plus2.0 Array [Hs133P_Hs_ENTREZG.Cd] GPL1463AffymetrixGeneChipHumanGenomeHGU133ACustomCDF [Affy_HGU133A_CDF_ENTREZG_10]. The data platform for GSE53757 is GPL570 [HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array. The data platform for GSE15641 is GPL96 [HG-U133A] Affymetrix Human Genome U133A Array. The robust multi-array average (RMA) method was utilized to standardize and annotate the corresponding data. All procedures performed in this study were in accordance with the Declaration of Helsinki (as revised in 2013) and approved by the Ethics Committee of the Shanghai Tenth People’s Hospital, School of Medicine in Tongji University (registration ID SHSY-IEC-4.0/19-47/01).

Statistical analysis

The ComBat of the sva packet of R language was used to correct two different chips. The differential genes of GSE99339, GSE96804, GSE53757, GSE15641, and GSE47183 were screened using the limma package of the R language. The standard that we selected was P<0.05, fold change >2 or <0.5. The interaction between genes was predicted using String V11.0, and the relationship between them was identified. The screening criterion was a combined score ≥0.4. The network map was visually constructed using the Cytoscape software (V3.5.1; http://cytos cape.org/). The genes are presented as points, while the relationship between the genes is represented by lines. The color depicts the size of degree, with a red color indicating a larger degree, and a yellow color indicating a smaller degree. The micro ribonucleic acids (miRNAs) of six genes that may be regulated were predicted using the miRNA Data Integration Portal (mirDIP) database and scored according to the prediction of each data set. The DIANA-MirPath v3 database was used to analyze the pathway and gene ontology (GO) enrichment of the miRNA predicted by each gene.

Identification the networks of DEGs

The protein-protein interaction (PPI) network of DN- and RCC-DEGs was predicted by string V11.0, and the relationship between them was obtained. The screening criterion was combined_score ≥0.4. And through the Cytoscape software (V3.5.1; http://cytos cape.org/) to visualize the construction of the network map, using dots to represent genes, and lines to represent the relationship between genes, where the color indicates the size of the degree, the color Reddish indicates that degree is larger, and yellowish indicates that degree is smaller.

Functional enrichment analysis

Kyoto Encyclopedia of Genes and Genomes (KEGG) and GO analysis used database to visually and comprehensively discover bioinformatics resources. We showed the biological process, molecular function and different biological functions of DN- and RCC-DEGs in REACTOME databases (v62; http://www.reactome) and DAVID (http://david.abcc.ncifcrf.gov/), respectively. DianamiRPath’s online tool (v3.0; http://www.microrna.gr/miRPa thv3) was used to evaluate the interaction between miRNA previously identified by predictive tools and the co-DEGs associated with DN and RCC.

Identification of co-DEGs between cancer and urogenital diseases

The Toxicogenomics database (http://ctdba se.org/) can be used to discover integrated gene-chemistry, gene-disease and chemical-disease interactions, then generate extended networks and estimate new associations. Then, these data were used to analyze the relationship between genes and kidney disease to determine the relationship and association or implicit association between these genes and diseases.

Results

Identification of DEGs

Firstly, the differential genes in DN were identified using the GSE99339, GSE96804, and GSE47183 datasets from the GEO database. For the GSE99339 dataset, the total number of probes was 10,947, of which the number of differential probes was 171 (up to 151 and down to 20). For the GSE96804 dataset, the total number of probes was 67,528, of which the number of differential probes was 2,012 (up to 1,552 and down to 460). For the GSE47183 dataset, the total number of probes was 11,961, of which the number of differential probes was 216 (up to 168 and down to 48). These three datasets were intersected and 53 intersecting genes were identified. Next, the pathway enrichment analysis was performed. We constructed a column of the function of significantly different genes, and the results are presented in . shows a bubble map depicting the significant differential gene pathways.
Figure 1

GO analysis and KEGG pathway enrichment. (A) DN-related GO analysis for DEGs; (B) KEGG pathway of DN-related DEGs; (C) RCC-related GO analysis for DEGs; (D) KEGG pathway of RCC-related DEGs, and dot colors represent negative Log10(P values). GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; DN, diabetic nephropathy; DEGs, differentially expressed genes; RCC, renal cell carcinoma.

GO analysis and KEGG pathway enrichment. (A) DN-related GO analysis for DEGs; (B) KEGG pathway of DN-related DEGs; (C) RCC-related GO analysis for DEGs; (D) KEGG pathway of RCC-related DEGs, and dot colors represent negative Log10(P values). GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; DN, diabetic nephropathy; DEGs, differentially expressed genes; RCC, renal cell carcinoma. Second, the differential genes in RCC were identified using the GSE53757 and GSE15641 datasets from the GEO database. For the GSE53757 dataset, the total number of probes was 54,665, of which the number of differential probes was 6,585 (up to 3,641 and down to 2,944). For the GSE15641 dataset, the total number of probes was 22,272, of which the number of differential probes was 2,050 (up to 1,649 and down to 2,944). These two datasets were intersected and 679 intersecting genes were identified. And the results of pathway enrichment analysis are shown in . The top 4 enriched biological process GO terms (cellular response to acid chemical, extracellular matrix organization, extracellular structure organization, and platelet degranulation) for these genes of DN-datasets are shown in a heat map in . The top 4 enriched biological process GO terms (extracellular structure organization, leukocyte migration, neutrophil activation, and response to oxygen levels) for these genes of RCC-datasets are represented in a heat map in .
Figure 2

Hierarchical clustering analysis of DN-related differentially expressed genes. (A) results of hierarchical clustering analysis for DEGs expression in relation to cellular response to acid chemical; (B) results of hierarchical clustering analysis for DEGs expression in relation to extracellular matrix organization; (C) results of hierarchical clustering analysis for DEGs expression in relation to extracellular structure organization; (D) results of hierarchical clustering analysis for DEGs expression in relation to platelet degranulation. Red, greater expression. Blue, less expression. DN, diabetic nephropathy; DEGs, differentially expressed genes.

Figure 3

Hierarchical clustering analysis of RCC-related differentially expressed genes (DEGs). (A) Results of hierarchical clustering analysis for the expression of DEGs in relation to the organization of extracellular structure; (B) results of hierarchical clustering analysis for the expression of DEGs in relation to leukocyte migration; (C) results of hierarchical clustering analysis for the expression of DEGs in relation to neutrophil activation; (D) results of hierarchical clustering analysis for the expression of DEGs in relation to response to oxygen levels. Red, high expression; Blue, low expression. RCC, renal cell carcinoma.

Hierarchical clustering analysis of DN-related differentially expressed genes. (A) results of hierarchical clustering analysis for DEGs expression in relation to cellular response to acid chemical; (B) results of hierarchical clustering analysis for DEGs expression in relation to extracellular matrix organization; (C) results of hierarchical clustering analysis for DEGs expression in relation to extracellular structure organization; (D) results of hierarchical clustering analysis for DEGs expression in relation to platelet degranulation. Red, greater expression. Blue, less expression. DN, diabetic nephropathy; DEGs, differentially expressed genes. Hierarchical clustering analysis of RCC-related differentially expressed genes (DEGs). (A) Results of hierarchical clustering analysis for the expression of DEGs in relation to the organization of extracellular structure; (B) results of hierarchical clustering analysis for the expression of DEGs in relation to leukocyte migration; (C) results of hierarchical clustering analysis for the expression of DEGs in relation to neutrophil activation; (D) results of hierarchical clustering analysis for the expression of DEGs in relation to response to oxygen levels. Red, high expression; Blue, low expression. RCC, renal cell carcinoma.

PPI network and co-DEGs analysis

PPI between the 53 intersecting genes identified from the 3 DN datasets was predicted using String V11.0. We visualized the relationships between the genes by constructing a PPI network, as shown in . The results showed that FN1 (degree =23), albumin (ALB) (degree =20), COL1A2 (degree =15), and MMP2 (degree =15) were hub genes in DN (with the degree indicating the number of other genes that the gene interacts with). Then, the PPI network of the 679 intersecting genes identified from the 2 RCC datasets was constructed to visualize their relationships (). The hub genes in RCC included ALB (degree =159), vascular endothelial growth factor A (VEGFA, degree =139), epidermal growth factor receptor (EGFR, degree =127), and FN1 (degree =123).
Figure 4

Protein-protein interaction (PPI) network analysis. (A) PPI network of DN-related DEGs; (B) PPI network of RCC-related DEGs. Red, greater degree; yellow, lesser degree; (C) Venn diagrams of DEGs. PPI network and Venn diagrams: (I) PPI networks of DEGs from A and B constructed using the String database (threshold >0.4); (II) Venn diagrams of DEGs related to DN and RCC, respectively. DN, diabetic nephropathy; DEGs, differentially expressed genes; RCC, renal cell carcinoma.

Protein-protein interaction (PPI) network analysis. (A) PPI network of DN-related DEGs; (B) PPI network of RCC-related DEGs. Red, greater degree; yellow, lesser degree; (C) Venn diagrams of DEGs. PPI network and Venn diagrams: (I) PPI networks of DEGs from A and B constructed using the String database (threshold >0.4); (II) Venn diagrams of DEGs related to DN and RCC, respectively. DN, diabetic nephropathy; DEGs, differentially expressed genes; RCC, renal cell carcinoma. Subsequently, we performed a joint analysis to determine which genes are co-differentially expressed in DN and RCC. VENN software was used to intersect the DEGs identified from the DN and RCC datasets. Twenty-four genes were obtained, and these are visualized in a Venn diagram in . More information is provided in .
Table 1

24 DEGs related to DN and RCC

GenesGene nameP value
ALB Albumin3.82757E−06
G6PC Glucose-6-phosphatase catalytic subunit0.00022495
EGF Epidermal growth factor0.000414252
PCK1 Phosphoenolpyruvate carboxykinase 17.27637E−05
ADH1B Alcohol dehydrogenase 1B (class I), beta polypeptide0.004123934
CLU Clusterin0.002382186
ARL4C ADP ribosylation factor like GTPase 4C0.000208268
COL15A1 Collagen type XV alpha 1 chain1.32548E−06
VSIG4 V-set and immunoglobulin domain containing 40.000470776
ACTN1 Actinin alpha 10.000178285
MS4A4A Membrane spanning 4-domains A4A0.000178285
RNASE6 Ribonuclease A family member k60.000251524
SPARCL1 SPARC like 19.03479E−05
OLFML2B Olfactomedin like 2B0.020197939
THBS2 Thrombospondin 20.000178285
APOC1 Apolipoprotein C10.000178285
COL1A2 Collagen type I alpha 2 chain0.008832521
COL6A3 Collagen type VI alpha 3 chain0.000178285
COL3A1 Collagen type III alpha 1 chain0.000178285
PLK2 Polo like kinase 20.001742339
FN1 Fibronectin 10.002382186
VCAN Versican0.000208268
KRT19 Keratin 190.003055744
TGFBI Transforming growth factor beta induced0.006804421

DN, diabetic nephropathy; RCC, renal cell carcinoma; DEGs, differentially expressed genes.

DN, diabetic nephropathy; RCC, renal cell carcinoma; DEGs, differentially expressed genes.

Prediction of disease-related genes using the Comparative Toxicogenomics Database

The Comparative Toxicogenomics Database (http://ctdbase.org/) was used to identify genes related to urogenital disease and cancer. Eleven genes were directly confirmed, and three genes [ALB, FN1, and transforming growth factor beta induced (TGFBI)] were confirmed to be related to DN. When the gene was scored more than 50 indirectly through the database, ALB, COL1A2, COL3A1, collagen type IV alpha 3 (COL6A3), FN1, G6PC, keratin 19 (KRT19), phosphoenolpyruvate carboxy kinase 1 (PCK1), polo like kinase 2 (PLK2), and TGFBI were found to be associated with RCC that these genes scored more than 50 indirectly. On the other hand, COL1A2, COL3A1, G6PC, and PCK1 were found through indirect prediction. Thus, we determined that ALB, FN1, COL1A2, COL3A1, G6PC, and PCK1 were related to DN and RCC. The related score of each gene in DN and RCC is shown in .
Figure 5

Relationship of urogenital disease and cancer related to co-expressed genes based on the Comparative Toxicogenomics Database (CTD). (A) The interactions of ALB in urogenital disease and cancer; (B) the interaction of COL1A2 in urogenital disease and cancer; (C) the interaction of COL3A1 in urogenital disease and cancer; (D) the interaction of FN1 in urogenital disease and cancer; (E) the interaction of G6PC in urogenital disease and cancer; (F) the interaction of PCK1 in urogenital disease and cancer.

Relationship of urogenital disease and cancer related to co-expressed genes based on the Comparative Toxicogenomics Database (CTD). (A) The interactions of ALB in urogenital disease and cancer; (B) the interaction of COL1A2 in urogenital disease and cancer; (C) the interaction of COL3A1 in urogenital disease and cancer; (D) the interaction of FN1 in urogenital disease and cancer; (E) the interaction of G6PC in urogenital disease and cancer; (F) the interaction of PCK1 in urogenital disease and cancer.

Hub gene detection and validation

We predicted the differential expression analysis for hub genes in tumor tissue and normal tissue using the Gene Expression Profiling Interactive Analysis (GEPIA) database (). COL1A2, COL3A1, and FN1 were significantly upregulated, while ALB, G6PC, and PCK1 were significantly downregulated, in RCC, compared with normal tissues (P<0.01). Among these genes, the expression levels of G6PC and PCK1 were significantly related to overall survival and disease-free survival in patients with RCC ().
Figure 6

Validation of the gene expression levels of hub genes between normal kidney and RCC tissues in the GEPIA database. (A) COL1A2 was significantly upregulated in RCC compared with normal tissues; (B) COL3A1 was significantly upregulated in RCC compared with normal tissues; (C) FN1 was significantly upregulated in RCC compared with normal tissues; (D) ALB was significantly downregulated in RCC compared with normal tissues; (E) G6PC was significantly downregulated in RCC compared with normal tissues; (F) PCK1 was significantly downregulated in RCC compared with normal tissues (P<0.01). The red * represents P<0.01. GEPIA, the Gene Expression Profiling Interactive Analysis; RCC, renal cell carcinoma; KIRC, kidney renal clear cell carcinoma.

Figure 7

Overall survival and disease-free survival analysis of key genes in RCC (based on TCGA data in GEPIA). (A) The expression levels of G6PC were significantly associated with the overall survival of patients with RCC; (B) the expression levels of PCK1 were significantly associated with overall survival in patients with RCC; (C) the expression levels of G6PC were significantly associated with disease-free survival in patients with RCC; (D) the expression levels of PCK1 were associated with disease-free survival in patients with RCC (P<0.05).

Validation of the gene expression levels of hub genes between normal kidney and RCC tissues in the GEPIA database. (A) COL1A2 was significantly upregulated in RCC compared with normal tissues; (B) COL3A1 was significantly upregulated in RCC compared with normal tissues; (C) FN1 was significantly upregulated in RCC compared with normal tissues; (D) ALB was significantly downregulated in RCC compared with normal tissues; (E) G6PC was significantly downregulated in RCC compared with normal tissues; (F) PCK1 was significantly downregulated in RCC compared with normal tissues (P<0.01). The red * represents P<0.01. GEPIA, the Gene Expression Profiling Interactive Analysis; RCC, renal cell carcinoma; KIRC, kidney renal clear cell carcinoma. Overall survival and disease-free survival analysis of key genes in RCC (based on TCGA data in GEPIA). (A) The expression levels of G6PC were significantly associated with the overall survival of patients with RCC; (B) the expression levels of PCK1 were significantly associated with overall survival in patients with RCC; (C) the expression levels of G6PC were significantly associated with disease-free survival in patients with RCC; (D) the expression levels of PCK1 were associated with disease-free survival in patients with RCC (P<0.05).

Identification of pathways and functional enrichment

We predicted the miRNAs of six genes using the mirDIP database, and rated these miRNAs according to each data forecast. The top five miRNAs of each gene were determined. The pathway and GO enrichment analysis of these miRNAs predicted for each gene was then carried out using the DIANA-MirPath v3 database (). The miRNAs predicted for the genes were as follows: ALB (hsa-miR-496 and hsa-miR-141-3p); COL1A2 (hsa-miR-29c-3p, hsa-let-7b-5p, hsa-let-7c-5p, hsa-let-7f-5p, and hsa-miR-29a-3p); COL3A1 (hsa-miR-29c-3p, hsa-miR-29a-3p, hsa-miR-29b-3p, hsa-miR-98-5p, and hsa-let-7b-5p); FN1 (hsa-miR-200c-3p, sa-miR-200b-3p, hsa-miR-429, hsa-miR-199a-3p, and hsa-miR-144-3p); G6PC (hsa-miR-200c-3p, hsa-miR-429, hsa-miR-200b-3p, hsa-miR-3163, and hsa-miR-29a-3p); and PCK1 (hsa-miR-1297, hsa-miR-548m, hsa-miR-330-3p, hsa-miR-101-3p, and hsa-miR-3163). Finally, we predicted the differential expression of the top five miRNAs in tumor tissue and normal tissue using StarBase (a website for predicting the RNA interactions). Among the predicted miRNAs, the expression levels of hsa-miR-200b-3ph, hsa-miR-429, and hsa-miR-29c-3p were significantly decreased in RCC.
Table 2

The gene ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enrichment among predicted miRNAs and co-DEGs

GenesPredicted miRNAsCategoryFunctionP value
ALB hsa-miR-496KEGG pathwaySteroid hormone biosynthesis5.27E−08
hsa-miR-141-3pHippo signaling pathway2.02E−05
Endocrine and other factor-regulated calcium reabsorption2.47E−05
GO termsMacromolecular complex assembly0.00030452
Epidermal growth factor receptor signaling pathway0.000423173
Post-translational protein modification0.000428322
G2/M transition of mitotic cell cycle0.000515818
Keratan sulfate biosynthetic process0.00053589
Fc-epsilon receptor signaling pathway0.000720702
Keratan sulfate metabolic process0.001811958
Sulfur compound metabolic process0.001941431
Phospholipid metabolic process0.005110673
ECM-receptor interaction1.46E−48
Mucin type O-glycan biosynthesis8.96E−09
KEGG pathwayPI3K-Akt signaling pathway0.006961302
TNF signaling pathway0.009107875
Signaling pathways regulating pluripotency of stem cells0.009974988
COL1A2 hsa-miR-29c-3pGO termsFc-epsilon receptor signaling pathway3.59E−17
hsa-let-7b-5pneurotrophin TRK receptor signaling pathway2.73E−15
hsa-let-7c-5pExtracellular matrix disassembly1.20E−12
hsa-let-7f-5pPost-translational protein modification3.56E−12
hsa-miR-29a-3pExtracellular matrix organization3.92E−09
Nucleobase-containing compound catabolic process8.99E−09
Platelet activation1.77E−08
COL3A1 hsa-miR-29c-3pKEGG pathwayECM-receptor interaction8.17E−49
hsa-miR-29a-3pMucin type O-glycan biosynthesis7.54E−09
hsa-miR-29b-3pFocal adhesion0.001207023
hsa-miR-98-5pPI3K-Akt signaling pathway0.006207862
hsa-let-7b-5pGO termsFc-epsilon receptor signaling pathway4.44E−17
Neurotrophin TRK receptor signaling pathway3.49E−15
Extracellular matrix disassembly1.42E−12
Post-translational protein modification4.28E−12
Cellular protein metabolic process1.98E−11
FN1 hsa-miR-200c-3pKEGG pathwayThyroid hormone signaling pathway0.024934027
hsa-miR-200b-3pCysteine and methionine metabolism0.028989042
hsa-miR-429Sphingolipid metabolism0.047606983
hsa-miR-199a-3pErbB signaling pathway0.048121598
hsa-miR-144-3pGO termsToll-like receptor TLR1:TLR2 signaling pathway0.010695034
Toll-like receptor TLR6:TLR2 signaling pathway0.010695034
Toll-like receptor 10 signaling pathway0.017791067
G6PC hsa-miR-200c-3pKEGG pathwayECM-receptor interaction1.62E−70
hsa-miR-429Focal adhesion3.49E−05
hsa-miR-200b-3pPI3K-Akt signaling pathway0.000700807
hsa-miR-3163Signaling pathways regulating pluripotency of stem cells0.001671859
hsa-miR-29a-3pGO termsCell death0.000888739
Fibroblast growth factor receptor signaling pathway0.001026574
Cellular lipid metabolic process0.0010844
MyD88-independent toll-like receptor signaling pathway0.001319258
PCK1 hsa-miR-1297KEGG pathwayHippo signaling pathway0.000298106
hsa-miR-548mThyroid hormone signaling pathway0.024032656
hsa-miR-330-3pSphingolipid metabolism0.037579593
hsa-miR-101-3pAdherens junction0.037579593
hsa-miR-3163GO termsCellular component disassembly involved in execution phase of apoptosis3.19E−05
Cell proliferation0.000266671
Cellular protein metabolic process0.000394966
Macromolecular complex assembly0.00042068
Fc-epsilon receptor signaling pathway0.000562009
Response to stress0.000562009
At the same time, we also carried out co-expression analysis for the miRNA-target interactions (). FN1 (predicted miRNAs: hsa-miR-200b-3p and hsa-miR-429), COL1A2 (predicted miRNA: hsa-miR-29c-3p), COL3A1 (predicted miRNA: hsa-miR-29c-3p), and G6PC (predicted miRNAs: hsa-miR-29a-3p and hsa-miR-200c-3p) were associated with DN and RCC.
Figure 8

Co-expression analysis for the miRNA-target interactions. (A) There is a significant negative correlation between hsa-miR-429 and FN1 with RCC; (B) there is a significant negative correlation between hsa-miR-200b-3p and FN1 with RCC; (C) there is a significant negative correlation between hsa-miR-29a-3p and G6PC with RCC; (D) there is a significant negative correlation between hsa-miR-200c-3p and G6PC with RCC; (E) there is a significant negative correlation between hsa-miR-29c-3p and COL1A2 with RCC; (F) there is a significant negative correlation between hsa-miR-29c-3p and COL3A1 with RCC (P<0.05).

Co-expression analysis for the miRNA-target interactions. (A) There is a significant negative correlation between hsa-miR-429 and FN1 with RCC; (B) there is a significant negative correlation between hsa-miR-200b-3p and FN1 with RCC; (C) there is a significant negative correlation between hsa-miR-29a-3p and G6PC with RCC; (D) there is a significant negative correlation between hsa-miR-200c-3p and G6PC with RCC; (E) there is a significant negative correlation between hsa-miR-29c-3p and COL1A2 with RCC; (F) there is a significant negative correlation between hsa-miR-29c-3p and COL3A1 with RCC (P<0.05).

Genetic alteration of hub genes

The alteration status of three key genes was analyzed using RCC patient data from The Cancer Genome Atlas (TCGA) of the cBioPortal for Cancer Genomics database. The frequency of alteration of each hub gene is shown in . FN1, COL1A2, and COL3A1 exhibited the most alteration (2%, 2%, and 1.7%, respectively), with amplification and messenger ribonucleic acid (mRNA) upregulation as the main types. The 3 hub genes were altered in 21 of 354 RCC patients (6%) (). shows the relationship of the 3 genes and the other 48 most frequently altered neighbor genes. FN1, COL1A2, and COL3A1 were significantly important in the network. Finally, we constructed a flow chart to summarize the all analysis process ().
Figure 9

Genetic alterations associated with 3 key genes. (A) A visual summary of genetic alterations (data from RCC in TCGA, provisional) shows the genetic alteration of 3 key genes which were altered in 21 (6%) of 354 RCC patients; (B) the total alteration frequency of 3 key genes is illustrated; (C) the network contains 51 nodes, including 3 key genes and the 50 most frequently altered neighbor genes. Relationship of 3 key genes is also illustrated.

Figure 10

A flow chart for analysis. GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; DN, diabetic nephropathy; RCC, renal cell carcinoma; CDEGs, co-expressed diferentially expressed genes; CTD, the Comparative Toxicogenomics Database; GEPIA, the Gene Expression Profiling Interactive Analysis.

Genetic alterations associated with 3 key genes. (A) A visual summary of genetic alterations (data from RCC in TCGA, provisional) shows the genetic alteration of 3 key genes which were altered in 21 (6%) of 354 RCC patients; (B) the total alteration frequency of 3 key genes is illustrated; (C) the network contains 51 nodes, including 3 key genes and the 50 most frequently altered neighbor genes. Relationship of 3 key genes is also illustrated. A flow chart for analysis. GO, gene ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; DN, diabetic nephropathy; RCC, renal cell carcinoma; CDEGs, co-expressed diferentially expressed genes; CTD, the Comparative Toxicogenomics Database; GEPIA, the Gene Expression Profiling Interactive Analysis.

Discussion

The incidence of renal cancer and diabetes occurring together is increasing. The elevated incidence of renal cancer, especially when it is associated with diabetes, should be of considerable concern. Although, due to a series of confounding factors, the relationship between DN and RCC may be unclear, these two diseases are clearly closely related. In clinical practice, early and careful screening of diabetic patients is needed to prevent the occurrence of RCC. The DEGs from the DN and RCC datasets were respectively examined using functional and pathway enrichment analysis. The GO database can help us to gain a better understanding of the relationship between gene functions. The value of GO analysis lies in first identifying the most important function of the target gene and the main or non-main function of the same gene, then judging whether the research target is accurate in a larger number of samples. The GO analysis method annotates gene functions of differential genes using the GO database to obtain all the functions that the genes participate in. It then uses Fisher’s exact test and the multiple comparison test to calculate the significance level (P value) and false discovery rate (FDR) of each function. Thus, the significant functions performed by different genes can be screened, with a P value <0.05 considered statistically significant. A targeted map can then be established according to the P value sequence based on the significant function, the number of genes contained in the analysis results, and their enrichment degree in the database. The smaller the P value, the higher the level of functional significance. By constructing the PPI network of DEGs, we can identify the action relationship between each gene in the network and other genes. We used String V11.0 to predict the interaction between genes, and the screening criterion was a combined score ≥0.4. Cytoscape software visualized the construction of the network map, using dots to represent genes and lines to represent the relationships between genes. The color depicted the size of the degree, with a red color indicating a larger degree, and a yellow color indicating a smaller degree. The degree refers to the number of genes associated with other genes; the larger the degree of a particular gene, the more genes that interact with it. We also performed a joint analysis of DN and RCC. By building a network of DEGs, we were able to identify the relationship between each gene and other genes in the network. According to the intersection of the two diseases, we established a Venn diagram using VENN software to show the DEGs that were co-differentially expressed in DN and RCC. A total of 24 genes were obtained by intersecting the DEGs from the 3 DN datasets with those from the 2 RCC datasets. We predicted the differential expression analysis for hub genes in both tumor tissue and normal tissue. According to the PPI network data, we screened the top 6 genes from the 24 obtained. These genes scored the highest on all datasets. We found that ALB, FN1, COL1A2, COL3A1, G6PC, and PCK1 were associated with both DN and RCC. ALB encodes serum ALB and acts on the colloid osmotic pressure of blood. To date, no study has explored the association between the hub gene of ALB and DN. ALB is downregulated in the tubulointerstitial tissue of patients with DN and may play a renal protective role in the prevention of diabetic tubulointerstitial injury (10). In tumor vascular endothelial cells, FN1 is highly expressed and promotes endothelial cell migration and angiogenesis (11,12). FN1 has been proven to potentially promote the progression of some tumors (13,14). Furthermore, some studies have shown that FN1 could play a critical role in promoting the invasion and metastasis of clear cell renal cell carcinoma (ccRCC) (15,16). The COL3A1 gene encodes the collagen found in extensible connective tissues. Su et al. found that LET-7d-COL3A1 acts through regulatory pathways in renal cell growth and metastasis. Let-7d inhibits the survival and proliferation of RCC by targeting chemokine (C-C motif) ligand 7 (CCL7) and COL3A1 (17). At the same time, we also predicted the co-expression analysis for the miRNA-target interactions. We predicted the miRNAs and rated these miRNAs according to each data forecast. We found that FN1, with the predicted miRNAs hsa-miR-200b-3p and hsa-miR-429, was related to both DN and RCC. COL1A2 (predicted miRNA: hsa-miR-29c-3p), COL3A1 (predicted miRNA: hsa-miR-29c-3p), and G6PC (predicted miRNAs hsa-miR-29a-3p and hsa-miR-200c-3p) were also associated with DN and RCC. The expression levels of the predicted miRNA hsa-miR-200b-3p was significantly downregulated in RCC compared with normal tissues, and there was a significant negative correlation between hsa-miR-200b-3p and FN1 in RCC. The expression levels of the predicted miRNA hsa-miR-29c-3p were also significantly downregulated in RCC compared with normal tissues and exhibited a significant negative correlation with COL1A2 in RCC. Furthermore, the predicted miRNAs hsa-miR-29a-3p and hsa-miR-200c-3p were negatively correlated with G6PC. The miRNA miR-200c-3p is involved in the tumorigenesis and progression of various cancers. Research has shown that the microR-200c-3p/ZEB2 loop plays a crucial role in prostate carcinoma tumor progression (18). Maolakuerban et al. found that miR-200c-3p inhibits cell migration and invasion of ccRCC by regulating the solute carrier family 6 member 1 (SLC6A1) gene (19). According to Li et al., miR-200c-3p suppresses the proliferative, migratory, and invasive capacities of nephroblastoma cells via targeting the fibroblast growth factor receptor substrate 2 (FRS2) gene (20). Also, miR-29a-3p has been reported to function as a tumor suppressor in several cancers. Zheng et al. found that downregulation of ribosomal protein S15a (RPS15A) by miR-29a-3p attenuated cell proliferation in colorectal carcinoma (21). Li et al. found that miR-200b-3p and miR-429-5p targeted the LIM domain kinase 1/cofilin 1 (LIMK1/CFL1) pathway to inhibit the growth and motility of breast cancer cells (22). Research has shown that miR-29c-3p regulates deoxyribonucleic acid (DNA)-methyltransferase 3 beta (DNMT3B) and large tumor suppressor kinase 1 (LATS1) methylation to inhibit tumor progression in hepatocellular carcinoma (23). Zhang et al. reported that miR-29c-3p regulates the biological function of colorectal cancer by targeting secreted protein acidic and cysteine rich (SPARC) (24). However, the biological functional role of miRNAs in RCC has not been well investigated. The expression of these genes needs to be verified in further well-designed studies. Although bioinformatics analyses have been performed, the specific molecular mechanisms have yet to be identified. In conclusion, the predicted miRNAs of FN1 (hsa-miR-200b-3p and hsa-miR-429), COL1A2 (hsa-miR-29c-3p), COL3A1 (hsa-miR-29c-3p), and G6PC (hsa-miR-29a-3p and hsa-miR-200c-3p) may be potential biomarkers or specific targets for the treatment of DN-related RCC. DN has a clear relationship with RCC, and further research is required to determine the underlying mechanisms of this relationship. The article’s supplementary files as
  24 in total

1.  Re: Design and endpoints of clinical trials in hepatocellular carcinoma.

Authors:  Massimo Di Maio; Bruno Daniele; Ciro Gallo; Francesco Perrone
Journal:  J Natl Cancer Inst       Date:  2008-10-28       Impact factor: 13.506

2.  Multiple-microarray analysis for identification of hub genes involved in tubulointerstial injury in diabetic nephropathy.

Authors:  Mengru Zeng; Jialu Liu; Wenxia Yang; Shumin Zhang; Fuyou Liu; Zheng Dong; Youming Peng; Lin Sun; Li Xiao
Journal:  J Cell Physiol       Date:  2019-02-13       Impact factor: 6.384

3.  Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma.

Authors:  H Takayasu; H Horie; E Hiyama; T Matsunaga; Y Hayashi; Y Watanabe; S Suita; M Kaneko; F Sasaki; K Hashizume; T Ozaki; K Furuuchi; M Tada; N Ohnuma; A Nakagawara
Journal:  Clin Cancer Res       Date:  2001-04       Impact factor: 12.531

Review 4.  Mechanisms through which diabetes mellitus influences renal cell carcinoma development and treatment: A review of the literature.

Authors:  Dominika Labochka; Barbara Moszczuk; Wojciech Kukwa; Cezary Szczylik; Anna M Czarnecka
Journal:  Int J Mol Med       Date:  2016-10-17       Impact factor: 4.101

5.  US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States.

Authors:  Rajiv Saran; Bruce Robinson; Kevin C Abbott; Jennifer Bragg-Gresham; Xiaoying Chen; Debbie Gipson; Haoyu Gu; Richard A Hirth; David Hutton; Yan Jin; Alissa Kapke; Vivian Kurtz; Yiting Li; Keith McCullough; Zubin Modi; Hal Morgenstern; Purna Mukhopadhyay; Jeffrey Pearson; Ronald Pisoni; Kaitlyn Repeck; Douglas E Schaubel; Ruth Shamraj; Diane Steffick; Megan Turf; Kenneth J Woodside; Jie Xiang; Maggie Yin; Xiaosong Zhang; Vahakn Shahinian
Journal:  Am J Kidney Dis       Date:  2019-11-05       Impact factor: 8.860

6.  Downregulation of RPS15A by miR-29a-3p attenuates cell proliferation in colorectal carcinoma.

Authors:  Zilei Zheng; Haitao Cui; Yi Wang; Weilong Yao
Journal:  Biosci Biotechnol Biochem       Date:  2019-07-13       Impact factor: 2.043

7.  Diabetes mellitus and cancer risk in a network of case-control studies.

Authors:  Cristina Bosetti; Valentina Rosato; Jerry Polesel; Fabio Levi; Renato Talamini; Maurizio Montella; Eva Negri; Alessandra Tavani; Antonella Zucchetto; Silvia Franceschi; Giovanni Corrao; Carlo La Vecchia
Journal:  Nutr Cancer       Date:  2012-04-20       Impact factor: 2.900

8.  Fibronectin promotes VEGF-induced CD34 cell differentiation into endothelial cells.

Authors:  Errol S Wijelath; Salman Rahman; Jacqueline Murray; Yatin Patel; Geoffrey Savidge; Michael Sobel
Journal:  J Vasc Surg       Date:  2004-03       Impact factor: 4.268

9.  hsa-miR-29c-3p regulates biological function of colorectal cancer by targeting SPARC.

Authors:  Shitong Zhang; Jianjun Jin; Xiaoxiao Tian; Lijuan Wu
Journal:  Oncotarget       Date:  2017-11-10

10.  Type 2 Diabetes Mellitus and Kidney Cancer Risk: A Retrospective Cohort Analysis of the National Health Insurance.

Authors:  Chin-Hsiao Tseng
Journal:  PLoS One       Date:  2015-11-11       Impact factor: 3.240

View more
  3 in total

1.  Integrated bioinformatics analysis reveals novel key biomarkers and potential candidate small molecule drugs in gestational diabetes mellitus.

Authors:  Varun Alur; Varshita Raju; Basavaraj Vastrad; Anandkumar Tengli; Chanabasayya Vastrad; Shivakumar Kotturshetti
Journal:  Biosci Rep       Date:  2021-05-28       Impact factor: 3.840

2.  mTOR/EGFR/iNOS/MAP2K1/FGFR/TGFB1 Are Druggable Candidates for N-(2,4-Difluorophenyl)-2',4'-Difluoro-4-Hydroxybiphenyl-3-Carboxamide (NSC765598), With Consequent Anticancer Implications.

Authors:  Bashir Lawal; Ching-Yu Lee; Ntlotlang Mokgautsi; Maryam Rachmawati Sumitra; Harshita Khedkar; Alexander T H Wu; Hsu-Shan Huang
Journal:  Front Oncol       Date:  2021-03-26       Impact factor: 6.244

Review 3.  Regulatory functions of miR‑200b‑3p in tumor development (Review).

Authors:  Sheng Chen; Yifeng Tu; Hang Yuan; Zhan Shi; Yang Guo; Wenjing Gong; Shiliang Tu
Journal:  Oncol Rep       Date:  2022-03-24       Impact factor: 3.906

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.